Literature DB >> 12475913

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells.

Francis C Lynn1, Stephen A Thompson, J Andrew Pospisilik, Jan A Ehses, Simon A Hinke, Nathalie Pamir, Christopher H S McIntosh, Raymond A Pederson.   

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. Here, we describe a novel pathway for the regulation of GIP receptor (GIPR) expression within clonal beta-cell lines, pancreatic islets, and in vivo. High (25 mM) glucose was able to significantly reduce GIPR mRNA levels in INS(832/13) cells after only 6 h. In contrast, palmitic acid (2 mM) and WY 14643 (100 microM) stimulated approximate doublings of GIPR expression in INS(832/13) cells under low (5.5 mM), but not high (25 mM), glucose conditions, suggesting that fat can regulate GIPR expression via PPARalpha in a glucose-dependent manner. Both MK-886, an antagonist of PPARalpha, and a dominant negative form of PPARalpha transfected into INS(832/13) cells caused a significant reduction in GIPR expression in low, but not high, glucose conditions. Finally, in hyperglycemic clamped rats, there was a 70% reduction in GIPR expression in the islets and a 71% reduction in GIP-stimulated insulin secretion from the perfused pancreas. Thus, evidence is presented that the GIPR is controlled at normoglycemia by the fatty acid load on the islet; however, when exposed to hyperglycemic conditions, the GIPR is down-regulated, which may contribute to the decreased responsiveness to GIP that is observed in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12475913     DOI: 10.1096/fj.02-0243fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  27 in total

1.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

2.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice.

Authors:  A Maida; B J Lamont; X Cao; D J Drucker
Journal:  Diabetologia       Date:  2010-10-23       Impact factor: 10.122

3.  Nutrigenomics, beta-cell function and type 2 diabetes.

Authors:  R Nino-Fong; Tm Collins; Cb Chan
Journal:  Curr Genomics       Date:  2007-03       Impact factor: 2.236

4.  The amount and types of fatty acids acutely affect insulin, glycemic and gastrointestinal peptide responses but not satiety in metabolic syndrome subjects.

Authors:  Chee-Yan Chang; M S Kanthimathi; Alexander Tong-Boon Tan; Kalanithi Nesaretnam; Kim-Tiu Teng
Journal:  Eur J Nutr       Date:  2016-09-08       Impact factor: 5.614

Review 5.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

Review 6.  The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus.

Authors:  Dima L Diab; David A D'Alessio
Journal:  Curr Diab Rep       Date:  2010-06       Impact factor: 4.810

7.  New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser.

Authors:  Y M Cho; T J Kieffer
Journal:  Diabetologia       Date:  2010-11-30       Impact factor: 10.122

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes.

Authors:  Dhananjay Gupta; Mina Peshavaria; Navjot Monga; Thomas L Jetton; Jack L Leahy
Journal:  Diabetes       Date:  2010-03-23       Impact factor: 9.461

Review 10.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.